This track will explore the latest breakthroughs in molecular oncology, focusing on the genetic and epigenetic factors that influence cancer development. Researchers are invited to present novel findings that enhance our understanding of tumor biology and therapeutic targets.
This session will delve into innovative immunotherapeutic approaches for cancer management, including checkpoint inhibitors and CAR T-cell therapy. Contributions that discuss clinical outcomes and mechanisms of action are particularly encouraged.
This track aims to highlight recent epidemiological studies that identify trends and risk factors associated with cancer incidence across diverse populations. Presentations will focus on data analysis and implications for public health initiatives.
This session will investigate the interactions between tumor cells and the immune microenvironment, emphasizing how these relationships influence cancer progression and treatment response. Researchers are invited to present studies that elucidate these complex dynamics.
This track will focus on the identification and validation of biomarkers for cancer diagnosis, prognosis, and treatment response. Submissions that discuss both laboratory and clinical applications of biomarkers are welcome.
This session will address effective strategies for cancer prevention and control, including lifestyle interventions and screening programs. Contributions that evaluate the impact of these strategies on population health are encouraged.
This track will explore cutting-edge genomic technologies and their applications in oncology, including next-generation sequencing and personalized medicine. Researchers are invited to share insights into how genomic data can inform treatment decisions.
This session will examine the dual role of the immune system in cancer progression and suppression, highlighting recent discoveries in immune evasion mechanisms. Presentations that explore therapeutic implications of these findings are encouraged.
This track will discuss the design, implementation, and outcomes of clinical trials in oncology, addressing both challenges and innovative solutions. Contributions that highlight patient-centered approaches and novel trial designs are particularly welcome.
This session will focus on the translation of basic immunological research into clinical applications for cancer treatment. Researchers are invited to present studies that bridge the gap between laboratory findings and therapeutic interventions.
This track will explore the global burden of cancer and the epidemiological factors that contribute to disparities in cancer outcomes. Presentations that address international collaborations and public health policies are encouraged.